JN
JNGHF
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
No data for this timeframe.
Vol
Recent Activity
May 29, 2026
clinical_trial_readout
Results Pending: HRS-9190 (Phase 2) — Completed 14d ago
Trial: Safety and Efficacy of HRS-9190 Compared to Rocuronium for Bolus Maintenance in Adults
Sponso
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $9.1B | 6.4% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $9.5B | 28.2% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $36.0B | 13.8% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $41.6B | 17.0% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 29, 2026
Clinical Trial
Safety and Efficacy of HRS-9190 Compared to Rocuronium for Bolus Maintenance in Adults
Phase Phase 2 — COMPLETED
May 29, 2026
clinical_trial_readout
Results Pending: HRS-9190 (Phase 2) — Completed 14d ago
Trial: Safety and Efficacy of HRS-9190 Compared to Rocuronium for Bolus Maintenance in Adults
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Phase: Phase
May 29, 2026
Clinical Trial
Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer
Phase Phase 2 — COMPLETED
May 23, 2026
Clinical Trial
A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
Phase Phase 2 — COMPLETED
May 4, 2026
Clinical Trial
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
Phase Phase 3 — ACTIVE_NOT_RECRUITING
May 4, 2026
Clinical Trial
Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
Phase Phase 2 — ACTIVE_NOT_RECRUITING
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: TACE+Camrelizumab+Apatinib mesylate (Phase 3)
Trial: A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
Sponsor: Jiangsu Hen
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: Camrelizumab (Phase 3)
Trial: A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk o
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: JSKN003 (Phase 2)
Trial: Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase:
May 2, 2026
clinical_trial_readout
T-90d Trial Readout: Camrelizumab (Phase 3)
Trial: A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk o
May 1, 2026
clinical_trial_readout
T-90d Trial Readout: TACE+Camrelizumab+Apatinib mesylate (Phase 3)
Trial: A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
Sponsor: Jiangsu Hen
May 1, 2026
clinical_trial_readout
T-90d Trial Readout: JSKN003 (Phase 2)
Trial: Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase: